6598-47-6

Basic information

• Product Name: 1,2-diacetyl-4-phenyl-1,2,4-triazolidine-3,5-dione
• Synonyms: 1,2-diacetyl-4-phenyl-1,2,4-triazolidine-3,5-dione
• CAS NO: 6598-47-6
• Molecular Formula: C₁₂H₁₁N₃O₄
• Molecular Weight: 261.23
• Mol File: 6598-47-6.mol
• Article Data: 4

Chemical Properties

• Melting Point: 168-170 °C
• Boiling Point: 368.5°C at 760 mmHg
• Flash Point: 161.2°C
• Appearance: /
• Density: 1.438g/cm³
• Vapor Pressure: 1.27E-05mmHg at 25°C
• Refractive Index: 1.61
• PKA: -1.11±0.20(Predicted)
• CAS DataBase Reference: 1,2-diacetyl-4-phenyl-1,2,4-triazolidine-3,5-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-diacetyl-4-phenyl-1,2,4-triazolidine-3,5-dione(6598-47-6)
• EPA Substance Registry System: 1,2-diacetyl-4-phenyl-1,2,4-triazolidine-3,5-dione(6598-47-6)

Safety Data

• Hazardous Substances Data: 6598-47-6(Hazardous Substances Data)

Usage

Abbreviation

DPTD

Application

Curing agent in the rubber industry

Process

Used in vulcanization to improve durability and elasticity

Physical state

White crystalline solid

Melting point

Around 143-145°C

Solubility

Soluble in organic solvents such as acetone and benzene

Additional function

Acts as an antioxidant

Purpose

Prevents degradation of rubber compounds due to heat and oxygen exposure

Safety

Proper handling and safety precautions should be taken to avoid potential health hazards

InChI:InChI=1/C12H11N3O4/c1-8(16)14-11(18)13(10-6-4-3-5-7-10)12(19)15(14)9(2)17/h3-7H,1-2H3

Upstream product

• 15988-11-1 4-Phenylurazole 
• 108-24-7 acetic anhydride 
• 6080-56-4 lead(II) acetate trihydrate 

Relevant articles and documents

1,2-diacetyl-4-phenyl-1,2,4-triazolidine-3,5-dione

The title crystal, C12H11N3O4, contains three essentially identical molecules in the asymmetric unit. The triazole rings in the three independent molecules are planar within 0.014 A. The N atom containing the ph

Method for control of hyperlipidemia

The present invention is directed to a method of controlling hyperlipidemia in mammals which comprises administering to a mammal an amount effective to control hyperlipidemia of a compound having hypolipidemic activity and the structural formula: STR1 wherein R1 is hydrogen, a C1 to C18 alkyl or substituted alkyl, a C2 to C18 alkenyl or substituted alkenyl, a C2 to C18 alkynyl or substituted alkynyl, a C4 to C10 cycloalkyl or substituted cycloalkyl, a C4 to C10 cycloalkenyl or substituted cycloalkenyl, phenyl, a substituted phenyl, cyano, phenalkyl, --CO--R9 or --Y--CO--R9 ; R2 is STR2 R3 and R4 can be the same or different and are each the same as R1 ; R5, R6 and R7 can be the same or different and are each hydrogen, a C1 to C18 alkyl or substituted alkyl, a C2 to C18 alkenyl or substituted alkenyl, a C1 to C18 alkynyl or substituted alkynyl, a C4 to C10 cycloalkyl or substituted cycloalkyl, a C4 to C10 cycloalkenyl or substituted cycloalkenyl, phenyl or substituted phenyl, phenalkyl, --CO--R9, or --Y--CO--R9, with the proviso that R5 and R6 together cannot be so bulky as to cause the compound to decompose; R8 is hydrogen, a C1 to C5 alkyl, a C4 to C10 cycloalkyl, --CO--R9 or Y--CO--R9 ; R9 is hydrogen, a C1 to C5 alkyl or substituted alkyl, a C2 to C5 alkenyl or substituted alkenyl, a C2 to C5 alkynyl or substituted alkynyl, phenyl or substituted phenyl, phenoxy or substituted phenoxy, a C1 to C5 alkoxy or substituted alkoxy, a C4 to C10 cycloalkyl or substituted cycloalkyl, a C4 to C10 cycloalkenyl or substituted cycloalkenyl, --NHC6 C5l , --NR10 R11 wherein R10 and R11 can be the same or different and are each hydrogen, a C1 to C5 alkyl or substituted alkyl, phenyl or substituted phenyl; Y is a C1 to C10 alkylene or substituted alkylene; R12 is --CO, --COH, --CS, --CSH, or a C1 to C4 alkylene group; and and the pharmaceutically acceptable salts, and mixtures thereof.